Comparison of Succinimidyl [125I]Iodobenzoate with Iodogen Iodination Methods to Study Pharmacokinetics and ADME of Biotherapeutics

[1]  Hua Bai,et al.  Pharmacokinetics, Tissue Distribution and Excretion of Recombinant Human Parathyroid Hormone 1–84 in Animals , 2013, Cell Biochemistry and Biophysics.

[2]  J. Ozer,et al.  Decreased Subcutaneous Bioavailability of an Oxyntomodulin Analog in a Controlled Release Formulation could be Caused by Skin Metabolism in Rats , 2012 .

[3]  Afshin Safavi,et al.  Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical Reagents , 2012, The AAPS Journal.

[4]  Lee Goodwin,et al.  Bioanalytical approaches to analyzing peptides and proteins by LC--MS/MS. , 2011, Bioanalysis.

[5]  M. Khalil,et al.  Molecular SPECT Imaging: An Overview , 2011, International journal of molecular imaging.

[6]  Heather Myler,et al.  Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.

[7]  Y. Vugmeyster,et al.  Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. , 2010, Journal of pharmaceutical sciences.

[8]  D. Rajalingam,et al.  Trichloroacetic acid‐induced protein precipitation involves the reversible association of a stable partially structured intermediate , 2009, Protein science : a publication of the Protein Society.

[9]  B. Gorovits.  Antidrug Antibody Assay Validation: Industry Survey Results , 2009, The AAPS Journal.

[10]  M. Schlumberger,et al.  131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients , 2008, Journal of Nuclear Medicine.

[11]  Denise M O'Hara,et al.  Critical ligand binding reagent preparation/selection: When specificity depends on reagents , 2007, The AAPS Journal.

[12]  R. Aebersold,et al.  Mass Spectrometry and Protein Analysis , 2006, Science.

[13]  A. A. van Well,et al.  Changes in the secondary structure of proteins labeled with 125I: CD spectroscopy and enzymatic activity studies , 2005 .

[14]  Binodh DeSilva,et al.  Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.

[15]  S. Jurisson,et al.  Modification of the structure of a metallopeptide: Synthesis and biological evaluation of 111in-labeled DOTA-conjugated rhenium-cyclized α-MSH analogues , 2002 .

[16]  S. Jurisson,et al.  α–melanocyte‐stimulating hormone peptide analogs labeled with technetium‐99m and indium‐111 for malignant melanoma targeting , 2002, Cancer.

[17]  S. Jurisson,et al.  Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. , 2002, Journal of medicinal chemistry.

[18]  A. Khalaj,et al.  A new and simple synthesis of N‐succinimidyl‐4‐[127/125I]iodobenzoate involving a microwave ‐ accelerated iodination step , 2001 .

[19]  G. V. van Dongen,et al.  Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  L. Potempa,et al.  Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[21]  M. Juweid,et al.  Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 , 1997, Cancer Immunology, Immunotherapy.

[22]  S. Strand,et al.  Optimization of radioiodination and biotinylation of monoclonal antibody chimeric BR96: an indirect labeling using N-succinimidyl-3-(tri-n-butylstannyl)benzoate conjugate. , 1996, Cancer biotherapy & radiopharmaceuticals.

[23]  D. Wilbur,et al.  Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  M. Zalutsky,et al.  Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate. , 1988, Cancer research.

[25]  R. Baughman,et al.  Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[26]  M. Zalutsky,et al.  A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. , 1987, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[27]  V. Cody,et al.  Rat liver iodothyronine monodeiodinase. Evaluation of the iodothyronine ligand-binding site. , 1986, The Journal of biological chemistry.

[28]  L. Osterman.  Methods of protein and nucleic acid research , 1984 .

[29]  R. Coleman,et al.  Comparison of iodine monochloride and modified chloramine-T radioiodination for in vivo protein studies. , 1977, Journal of Laboratory and Clinical Medicine.

[30]  W. Hunter,et al.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. , 1973, The Biochemical journal.